What is a stock summary page? Click here for an overview.
Business Description
Tci Gene Inc
ISIN : TW0006879000
Share Class Description:
ROCO:6879: Ordinary SharesDescription
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1079.91 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 112.66 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 9.16 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.7 | |||||
| 3-Year EBITDA Growth Rate | -26.7 | |||||
| 3-Year EPS without NRI Growth Rate | -22 | |||||
| 3-Year FCF Growth Rate | -24.9 | |||||
| 3-Year Book Growth Rate | 36.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.16 | |||||
| 9-Day RSI | 43.82 | |||||
| 14-Day RSI | 42.92 | |||||
| 3-1 Month Momentum % | 7.69 | |||||
| 6-1 Month Momentum % | -7.44 | |||||
| 12-1 Month Momentum % | -29.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.82 | |||||
| Quick Ratio | 9.38 | |||||
| Cash Ratio | 8.26 | |||||
| Days Inventory | 131.58 | |||||
| Days Sales Outstanding | 93.85 | |||||
| Days Payable | 147.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.15 | |||||
| Dividend Payout Ratio | 0.45 | |||||
| Forward Dividend Yield % | 2.15 | |||||
| 5-Year Yield-on-Cost % | 2.15 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 2.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.72 | |||||
| Operating Margin % | 16.05 | |||||
| Net Margin % | 16.2 | |||||
| FCF Margin % | 15.62 | |||||
| ROE % | 5.63 | |||||
| ROA % | 4.84 | |||||
| ROIC % | 34.37 | |||||
| 3-Year ROIIC % | -60.58 | |||||
| ROC (Joel Greenblatt) % | 175.09 | |||||
| ROCE % | 6.64 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.89 | |||||
| PE Ratio without NRI | 20.96 | |||||
| Price-to-Owner-Earnings | 61.79 | |||||
| PS Ratio | 3.54 | |||||
| PB Ratio | 1.27 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| Price-to-Free-Cash-Flow | 22.68 | |||||
| Price-to-Operating-Cash-Flow | 21.61 | |||||
| EV-to-EBIT | 6.09 | |||||
| EV-to-EBITDA | 5.07 | |||||
| EV-to-Revenue | 1.19 | |||||
| EV-to-FCF | 8.51 | |||||
| Price-to-GF-Value | 0.62 | |||||
| Price-to-Graham-Number | 1.09 | |||||
| Price-to-Net-Current-Asset-Value | 1.42 | |||||
| Price-to-Net-Cash | 1.73 | |||||
| Earnings Yield (Greenblatt) % | 16.43 | |||||
| FCF Yield % | 4.42 | |||||
| Forward Rate of Return (Yacktman) % | -5.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tci Gene Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 347.539 | ||
| EPS (TTM) (NT$) | 2.12 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 15.86 | ||
| 14-Day RSI | 42.92 | ||
| 14-Day ATR (NT$) | 1.646209 | ||
| 20-Day SMA (NT$) | 47.7 | ||
| 12-1 Month Momentum % | -29.11 | ||
| 52-Week Range (NT$) | 41 - 81.5 | ||
| Shares Outstanding (Mil) | 26.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tci Gene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tci Gene Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tci Gene Inc Frequently Asked Questions
What is Tci Gene Inc(ROCO:6879)'s stock price today?
The current price of ROCO:6879 is NT$46.40. The 52 week high of ROCO:6879 is NT$81.50 and 52 week low is NT$41.00.
When is next earnings date of Tci Gene Inc(ROCO:6879)?
The next earnings date of Tci Gene Inc(ROCO:6879) is .
Does Tci Gene Inc(ROCO:6879) pay dividends? If so, how much?
The Dividend Yield %  of Tci Gene Inc(ROCO:6879) is 2.15% (As of Today), Highest Dividend Payout Ratio of Tci Gene Inc(ROCO:6879) was 4.52. The lowest was 0.45. And the median was 0.69. The  Forward Dividend Yield % of Tci Gene Inc(ROCO:6879) is 2.15%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers